For health care professionals in EUROPE except those practicing in France as the following pages are intended to all International health care professionals and are not in compliance with the French Advertising law N°2011-2012 dated 29th December 2011 article 34. Other health care professionals should select their country in the top right corner of the website.
Please note that the following pages are exclusively reserved for health care professionals in countries with applicable health authority product registrations. To the extent this site contains information, reference guides and databases intended for use by licensed medical professionals, such materials are not intended to offer professional medical advice. Prior to use, please consult device labeling for prescriptive information and operating instructions.
This Website is protected by the laws on copyright and by the relevant international conventions. It is strictly forbidden to make copies, whether partial or total and on whichever media without prior approval.
The largest, prospective, real-world, Y-90 study of primary liver cancer in 1,000+ patients using TheraSphere Y-90 Glass Microspheres.
First multicentre, 1,000+ patient study that builds on previously published TheraSphere landmark trials which span the Barcelona Clinic Liver Cancer (BCLC) guidelines
Data from 30+ sites using contemporary techniques and dosing
The study aims to gather data on effectiveness, patient quality of life (QoL), and safety with use of TheraSphere Y-90 glass microspheres in real-world clinical settings in France.
Overall survival (OS) from time of TheraSphere treatment and quality of life, as assessed by using the functional assessment of Cancer Therapy – Hepatobiliary (FACT-Hep) questionnaire.
Grade ≥3 AEs, SAEs, tumour response, tumor marker response, subsequent therapy, and dosimetry evaluations.
AE = Adverse event. SAE = Serious adverse event.
This study is sponsored by Boston Scientific. Final results are expected in 2025 and will include full patient population with additional information on quality of life, safety and dosimetry.
Garin E, Bailly C, Letang A et al. Abstract No. 257 • Featured Abstract The PROACTIF French Registry Study of Y-90 Glass Microspheres for the Treatment of Liver Malignancies: Interim Analysis of 670 Hepatocellular Carcinoma (HCC) Patients. J Vasc Interv Radiol. 2024 Mar 35(3):S113 doi: https://doi.org/10.1016/j.jvir.2023.12.295 (updated dataset for oral presentation at SIR March 2024)
*HCC = hepatocellular carcinoma
*iCC = intrahepatic cholangiocarcinoma
Caution:
The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings, and instructions for use can be found in the product labelling supplied with each device or at www.IFU-BSCI.com. Products shown for INFORMATION purposes only and may not be approved or for sale in certain countries. This material not intended for use in France.
TheraSphere is a registered trademark of Theragenics Corporation, used under license by Boston Scientific Medical Device Limited, a wholly owned indirect subsidiary of Boston Scientific Corporation.
